ORPHA:439746
Secondary polyarteritis nodosa
Also known as: Secondary PAN · Secondary periarteritis nodosa
Publications
42
41.2th percentile
Trials
0
Interventional, condition-specific
Researchers
287
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Secondary polyarteritis nodosa (PAN) is a rare serious form of PAN characterized by vasculitis in a background of viral infection, primarily with hepatitis B virus (HBV).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018594
- UMLS:C5680050
Additional Mondo synonyms (2)
secondary PAN · secondary periarteritis nodosa
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
42 matched papers (26 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 9 for broader category polyarteritis nodosa
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
42
42 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
42 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
26 in the last 10 years · high confidence · 41.2th percentile (publications denominator)
Phrase hits: 42 · MeSH hits: 0
Who's working on it?
287
Distinct author names in 42 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Agard C2 papers · 2026
Nantes Université, CHU Nantes, Service de médecine interne, F-44000, Nantes, France.
Papers in Europe PMC - 02Baillet C2 papers · 2026
CHU de Lille, Département de Médecine Nucléaire F-59000 Lille, France.
Papers in Europe PMC - 03
- 04Guillevin L2 papers · 2023
Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
Papers in Europe PMC - 05Huglo D2 papers · 2026
CHU de Lille, Département de Médecine Nucléaire F-59000 Lille, France.
Papers in Europe PMC - 06Ledoult E2 papers · 2026
Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation F-59000 Lille, France; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM) F-59000 Lille, France.
Papers in Europe PMC - 07Martinage N2 papers · 2026
CHU de Lille, Département de Médecine Nucléaire F-59000 Lille, France. Electronic address: nicolas.martinage@chu-lille.fr.
Papers in Europe PMC - 08Mekinian A2 papers · 2026
Department of Internal Medicine, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France.
Papers in Europe PMC - 09Nguyen Y2 papers · 2026
Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France; Autoimmunity Team, Immunology of Viral Infections and Autoimmune Diseases, INSERM U1184, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Papers in Europe PMC - 10Puéchal X2 papers · 2026
Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 9 trials are registered for polyarteritis nodosa, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
9 interventional trials matched polyarteritis nodosa, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: polyarteritis nodosa
9
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT02939573·RECRUITING·A Randomized Multicenter Study for Isolated Skin Vasculitis
Conditions: Primary Cutaneous Vasculitis · Cutaneous Polyarteritis Nodosa · IgA Vasculitis · Henoch-Schönlein Purpura·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Secondary polyarteritis nodosa" OR "Secondary PAN" OR "Secondary periarteritis nodosa"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Secondary polyarteritis nodosa" OR "Secondary PAN" OR "Secondary periarteritis nodosa"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"polyarteritis nodosa"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T16:19:00.516Z